Marshall Wace’s Dyne Therapeutics DYN Stock Holding History

Marshall Wace’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.51M	Sell	83,147 -593,832	-88%	-$10.2M	﹤0.01%	1935
2025 Q4	$13.2M	Sell	676,979 -2,336,398	-78%	-$44.2M	0.01%	769
2025 Q3	$38.1M	Buy	3,013,377 +2,565,570	+573%	+$29.3M	0.04%	409
2025 Q2	$4.26M	Buy	+447,807	New	+$4.93M	﹤0.01%	1222
2025 Q1	–	Sell	-24,501	Closed	-$577K	–	2727
2024 Q4	$577K	Buy	+24,501	New	+$725K	﹤0.01%	1982
2024 Q3	–	Sell	-273,567	Closed	-$9.65M	–	2602
2024 Q2	$9.65M	Buy	273,567 +219,862	+409%	+$6.39M	0.01%	743
2024 Q1	$1.52M	Buy	+53,705	New	+$1.21M	﹤0.01%	1482
2023 Q4	–	Sell	-22,052	Closed	-$198K	–	2271
2023 Q3	$198K	Hold	22,052	–	–	﹤0.01%	1976
2023 Q2	$248K	Sell	22,052 -110,292	-83%	-$1.3M	﹤0.01%	2189
2023 Q1	$1.52M	Buy	132,344 +110,292	+500%	+$1.43M	﹤0.01%	1609
2022 Q4	$256K	Sell	22,052 -42,858	-66%	-$496K	﹤0.01%	2618
2022 Q3	$824K	Sell	64,910 -284,369	-81%	-$3.26M	﹤0.01%	2497
2022 Q2	$2.4M	Hold	349,279	–	–	﹤0.01%	1870
2022 Q1	$3.37M	Hold	349,279	–	–	0.01%	1711
2021 Q4	$4.15M	Buy	349,279 +327,227	+1,484%	+$4.6M	0.01%	1503
2021 Q3	$358K	Hold	22,052	–	–	﹤0.01%	2568
2021 Q2	$464K	Buy	+22,052	New	+$415K	﹤0.01%	2168

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Marshall Wace's DYN Position: Q1 2026 in Review

Marshall Wace reduced its Dyne Therapeutics (DYN) stake by 88% in Q1 2026, selling an estimated $10.2M and leaving 83,147 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Marshall Wace first reported a position in DYN in Q2 2021 and has held it in 17 quarters since. The position peaked at $38.1M in Q3 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Marshall Wace held 83,147 shares of Dyne Therapeutics worth $1.51M as of Q1 2026.
Marshall Wace sold 593,832 Dyne Therapeutics shares in Q1 2026, an estimated $10.2M.
Dyne Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1935 holding.
Marshall Wace first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 17 quarters since.
Marshall Wace's Dyne Therapeutics position peaked at $38.1M in Q3 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.